Business Description
Lexeo Therapeutics is a New York-based clinical-stage company developing gene therapies for serious heart and brain conditions that currently have few or no effective treatment options. Its pipeline includes several candidates targeting inherited and acquired cardiac disorders, such as Friedreich ataxia cardiomyopathy, arrhythmogenic cardiomyopathy, and hypertrophic cardiomyopathy, as well as APOE4-associated Alzheimer's disease. The company works closely with Cornell University through multiple research and licensing agreements to advance its programs from early laboratory studies through clinical trials. Founded in 2017, Lexeo is building a focused portfolio aimed at diseases where genetic intervention could make a meaningful difference for patients.
